Core Viewpoint - Sanofi showcases its commitment to the Chinese market and patients by presenting its advancements in high-quality manufacturing, supply chain, immunology innovations, and patient health empowerment at the 3rd China International Supply Chain Promotion Expo [1] Group 1: Company Commitment and Achievements - Sanofi has been operating in China for over 40 years, establishing a comprehensive ecological value chain that includes local R&D, manufacturing, and patient services [1] - The year 2023 marks the 30th anniversary of Sanofi's localized manufacturing in China, highlighting its long-term commitment to the market [1] - Sanofi plans to invest €1 billion in a new production base in Beijing by December 2024, focusing on end-to-end localized production capabilities for insulin products to meet the growing demand from diabetes patients in China [1] Group 2: Supply Chain and Manufacturing Innovations - At the expo, Sanofi presented a model demonstrating the entire process of flu vaccine production, from France to local manufacturing in Shenzhen, showcasing its supply chain and manufacturing advantages [2] - The Shenzhen factory represents a significant upgrade from "manufacturing" to "intelligent manufacturing," with all key steps of flu vaccine production being localized [2] - Sanofi employs a comprehensive quality management system that ensures traceability throughout the vaccine storage and transportation process, reinforcing vaccine safety [2]

在上海美容博览会（以下简称"CBE"）到来之际，"怎样找到好产品"的呼声越来越高。 当下，美妆行业进入"竞质"新周期，消费者对美妆产品的功效追求及自身科学素养已达到前所 未有的高度。虽然以质取胜是亘古不变的真理，但什么是"质"以及背后的路径，已经发生巨大 改变。 一方面，市场端对产品品质需求仍在上升，但另一方面，独立研发成本、合规成本仍在不断上 涨 ， 而 中 国 市 场 " 好 产 品 " 的 另 一 重 关 键 定 义 是 " 能 够 人 人 用 得 起 的 产 品 " 。 这 意 味 着 " 既 要 又 要"的极端的"质价比"追求，正在深度考验中国供应链企业的实力。 在今年的CBE上，中国美妆供应链企业会交出怎样的答案？ "功效太卷了" "价格卷到头了"是近年来美妆行业普遍心声。 具 体 表 现 在 消 费 者 端 ， 消 费 者 不 仅 需 要 强 劲 的 功 效 ， 还 要 求 产 品 拥 有 真 实 的 基 础 研 究 作 为 支 撑，清晰的功效机理，并配备专业的功效、测评数据作为论证基础。"高品质"的定义进一步演 化成为对完整科研链路，强大品控能力的具体需求。 此外，在极度同质化的高功效内卷中， ...